Goldberg Law PC ( www.Goldberglawpc.com) reminds investors in Celladon Corporation ("Celladon" or the "Company") (NASDAQ: CLDN), who purchased or otherwise acquired shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period"), of the August 31, 2015 deadline to file a motion to be appointed as lead plaintiff.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Celladon is a biotechnology company focused on developing gene therapies for cardiovascular diseases. The complaint alleges that the Company made false and/or misleading statements and failed to disclose adverse information regarding MYDICAR, its lead drug candidate for the treatment of enzyme deficiency in patients experiencing heart failure. On April 26, 2015, the Company reported that its Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. The Company had omitted to mention that the CUPID1 trial was significantly smaller, and that success from the first trial was not indicative of any success in the CUPID2 trial. When the truth was revealed, the stock dropped causing damage to investors.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com, or visit our website at Goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150717005840/en/

Copyright Business Wire 2010